227Th-PSMA-TTC (227Th-BAY2315497) is a Thorium-227 labelled PSMA-targeted full IgG antibody based therapeutic with 227Th linked through the Chelating agent 3,2-HOPO.

The priority indication for this drug is obviously metastatic castration resistant prostate cancer. The cold antibody was also developed in the indication glioblastoma.

A Phase I study recruiting 111 patients was initiated in October 2018. It is expected to be completed in September 2023.

Target/Mechanism: PSMA

Leading Emitter: Alpha particle (α)